logo.gif
Auris Medical Provides Update on Bentrio Program in Allergy
07 mai 2021 09h05 HE | Auris Medical AG
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...
Zoom-In on Health Equity: AAFA Asks Congress to Tackle Racial Disparities in Asthma and Allergy
30 avr. 2021 14h22 HE | Asthma and Allergy Foundation of America
Washington, D.C, April 30, 2021 (GLOBE NEWSWIRE) -- Each year, the Asthma and Allergy Foundation of America (AAFA) brings patient spokespeople and advocates from across the nation to Congress to...
AAFA Meets Asthma and Allergy Awareness Month with 31 DAYS OF ACTION
29 avr. 2021 14h03 HE | Asthma and Allergy Foundation of America
Washington, D.C, April 29, 2021 (GLOBE NEWSWIRE) -- May is National Asthma and Allergy Awareness Month. This year the Asthma and Allergy Foundation of America (AAFA) is encouraging everyone to look...
logo.gif
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
13 avr. 2021 07h45 HE | Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Chief Operating Officer
25 mars 2021 09h10 HE | Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
12 mars 2021 09h30 HE | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
Miravo Healthcare to present at the Q1 Virtual Investor Summit
11 mars 2021 07h35 HE | Nuvo Pharmaceuticals Inc.
MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare™ today announced that Jesse Ledger, President...
intrommune_icon_500x500.png
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
23 févr. 2021 12h00 HE | Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
AAFA’s 2021 Allergy Capitals™ Report Ranks Top U.S. Cities for Seasonal Allergies
23 févr. 2021 05h00 HE | Asthma and Allergy Foundation of America
Washington D.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) released its annual Allergy Capitals™ report for 2021. The report identifies the most...
intrommune_icon_500x500.png
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
04 févr. 2021 09h13 HE | Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...